Terns Pharmaceuticals (TERN) Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. IBM
5. META
6. MU
7. BLZE
8. PRIM
9. ACN
10. NVDA

Go back to Terns Pharmaceuticals (TERN) Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
(NASDAQ: TERN) Delayed: 52.95 --0 (-0%)
Previous Close $52.95    52 Week High $ 
Open $52.95    52 Week Low $ 
Day High $52.95    P/E N/A 
Day Low $52.95    EPS $ 
Volume 11,430